Jamieson Bondarenko, a Director, acquired 5,000,000 Common Shares on a direct ownership basis at a price of $0.100 through a prospectus or prospectus exempt offering on March 25th, 2019. This represents a $500,000 investment into the company's shares and an account share holdings change of 27.3%.
BriaCell Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
BriaCell Therapeutics Corp. is a Canada-based immuno-oncology biotechnology company, which develops treatments for cancer. Its lead product candidate, Bria-IMT, is being tested in a clinical trial in combination with pembrolizumab in patients with advanced breast cancer. The Company also is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer patients, and BriaDX, its companion diagnostic test. The Company's preclinical small molecule program consists of protein kinase C delta inhibitors for cancer and fibrotic diseases. BriaCell Therapeutics Corp. (BCT) has a high amount of executive buying compared to its micro-cap peers in the market over the past three months. According to regulatory filings yesterday, one insider has invested a total amount of $500,000.
No Comments